The aim of the study was to define prognostic factors of overall and event-free survival in patients with germ cell tumors progressing after platinum-based induction chemotherapy with or without surgery. A total of 98 progressing patients were identified out of 700 patients with germ cell tumors treated with platinum-based induction chemotherapy in National Cancer Institute in Bratislava with or without surgery. 98 progressing patients received first salvage chemotherapy from October 1986 to November 2007 due to progression after a previous partial or complete response to induction chemotherapy as well as patients who failed to achieve favourable response to primary therapy. Prognostic factors of survival and event-free survival after first salvage chemotherapy were assessed by univariate analysis. For all 98 progressing patients the median time from the start of induction chemotherapy to progression was 10,2 months (range: 0-256,7 months). 24 (24 %) patients relapsed after 2 years. Median overall survival time following progression was 25,4 months. Estimated 2-and 5-year overall survival rate for all progressing patients was 46 % (95 % CI 41-61%) and 24 % (95% CI 31-51%) respectively. Survival after first salvage chemotherapy was significantly enhanced for patients with age more than 40 years at primary diagnosis, nonvisceral metastasis at the time of induction chemotherapy, prior CR to induction chemotherapy, progression-free interval > 2 years, serum human chorionic gonadotropin level at relapse above or bellow 100 IU/l, a normal serum lactate dehydrogenase level at relapse, one site of metastasis at relapse, treatment with cisplatin-based first salvage chemotherapy, first regimen VIP and favourable response to salvage chemotherapy. Estimated 2-and 5-year event-free survival rate for all patients was 30% (95% CI 24-43% ) and 16%(95% CI 19-37% ) respectively. As a significant favourable prognostic factors of event-free survival were identified: prior CR to induction chemotherapy, progression-free interval > 2 years, one site of metastasis at relapse, treatment with cisplatin-based first salvage chemotherapy, first line salvage regimen VIP and favourable response to salvage chemotherapy. Identification of prognostic features in patients with germ cell tumors progressing after platinum-based induction chemotherapy may direct salvage therapy and requires further investigation of new combination of salvage therapy for those with poor prognosis. Our study showed the indispensable revaluating of chemosenzitivity in patients with late relapses and therapeutic value of additive surgical approach after salvage chemotherapy in patients with reccurent germ cell tumors.
patients with relapsed or platinum-refractory germ cell tumors is unsatisfying, range from 30 to 40 %. Identifying reliable prognostic features in patients with relapsed or platinum-refractory gem cell tumors may direct salvage therapy and could improve survival rate for these patients. Few studies were trying to identify prognostic factors in patients with recurrent germ cell tumors [0, 0, 0, 0, 0]. Cardinal Fossa's et al study identified 3 independent prognostic parameters in patients with recurrent germ cell tumors. Based on this study, Sammler et al evaluated the impact of determined prognostic factors in patients with germ-cell tumors relapsing or progressing after cisplatin-based first-line chemotherapy. They suggested a clinical benefit for patients with poor prognosis features receiving high-dose chemotherapy [0] . The aim of our study was to establish prognostic factors of overall and event-free survival in patients with relapsed or primary refractory germ cell tumors which may help to determine patients with poor prognosis, considering them as candidates for high-dose chemotherapy or clinical trials in the future.
Patients and methods
Total of 98 progressing patients were identified out of more than 700 patients with germ cell tumors treated with platinum-based induction chemotherapy in our centre with or without surgery. Our study represents an analysis of patients who progressed during or following platinum-based induction chemotherapy. This includes patients who never achieved a response (primary refractory) and those with new disease activity after achieving a complete or partial response to induction chemotherapy.
All patients were treated with platinum-based induction chemotherapy between November 1980 and April 2007. 5 patients belonged to stage I.A at the time of diagnosis (without lymph or visceral metastases). These patients received induction chemotherapy at the time of 1.relapse. Due to this we evaluated metastatic extent of disease at the time of start of induction chemotherapy in all patients. Patients with operable residual post-chemotherapy masses underwent surgery to remove them.
All patients in the study received both induction and first salvage chemotherapy. However, 5 patients relapsed in retroperitoneum but they did not receive first salvage chemotherapy at the time of that first relapse, 4 patients underwent complete retroperitoneal lyphadenectomy (RPLA) and 1 patient received radiotherapy to retroperitoneum extra muros. Those patients received first salvage chemotherapy at the time of second relapse in our centre (we evaluated their characteristics at the time of second relapse prior to first salvage chemotherapy).
Histological subtyping of the primary germ cell tumor was based on the Mostofi and Sesterhenn adaptation of Dixon/ Moore classification [0] .
Complete response to therapy (CR) was defined as clinical and radiological absence of all tumor manifestations (including normalization of serum alpha fetoprotein (AFP) and human chorionic gonadotropin (hCG), or complete resection of residual mature teratoma or necrotic/fibrotic tumor tissue. Incomplete response to therapy (IR=PRnm+) was defined as radiological decrease of malignant disease more than 50% with persistently elevated tumor markers (without serially rising values) or histological findings of residual cancer in resection specimen. Stabilisation (SD) was defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progression. Partial remission marker negative (PRnm-) comprised patients with residual tumor masses with normal level of serum tumor Prognostic factors of survival from the date of progression were identified. Potential prognostic factors included patient characteristics at initial diagnosis and induction chemotherapy, response to induction chemotherapy, duration of progression free-interval, patient characteristics at relapse, salvage regimen, response to salvage regimen and surgical intervention after first salvage regimen ( Table 1, Table 3 ).
Time to progression was measured from the date of start of induction chemotherapy to the date of relapse or progression.
Overall survival time was measured from the date of diagnosis of progression to the date of death or date last seen.
Event-free survival was measured from the start of first salvage chemotherapy to the date of relapse or progression, or the date of death or date last seen.
In the final analysis patients with missing data on any factor were excluded case by case.
Survival distributions were estimated by Kaplan-Meier method and survival curves were compared using logrank test.
Results
Ninety eight patients with germ cell tumors relapsed. Of these, 59 (60 %) have died and the median follow-up time of those still alive is 57,5 months (1,7-226,3 months).
Primary tumor site was in testes in 86 (88 %) of our patients. 44 (46 %) patients belonged to the good, 15 (16 %) The median time to progression from start of induction chemotherapy was 10,2 months (range: 0-256,7 months) for all patients. 4/98 (4 %) patients progressed within 4 weeks after completion of induction chemotherapy (primary refractory patients). 24/98 (24 %) patients progressed after more than 2 years after completion of induction chemotherapy, whereas all of them achieved favourable response to induction chemotherapy (13 patients CR, 11 patients PRnm-).
Median survival time following progression was 25,4 months and the estimated 2-and 5-year survival was 46 % (95% CI 41-61%) and 24 % (95% CI 31-51%).
Patients characteristics at the time of induction chemotherapy are described in Table 1 .
The majority of patients (52%) received four courses of induction chemotherapy. 56 (57 %) patients received combination chemotherapy BEP/EP.
Details of induction regimens are described in Table 2 . Twenty nine (30 %) of patients underwent RPLA after induction chemotherapy, whereas complete resection was in 16 (55 %) cases and incomplete resection of necrotic/fibrotic tissue or mature teratoma in 13 (45 %). 1 patient refused RPLA after induction chemotherapy. 8 (8 %) patients underwent metastasectomy in other locations, while complete resection of pulmonary metastases was achieved in 4 cases, in 2 patients complete resection of mediastinal masses and in last 2 patients just incomplete resection of mediastinal masses was achieved. None of residual masses removed by surgery demonstrated viable residual cancer.
Detailed data on patients characteristics at relapse are described in Table 3 .
First salvage chemotherapy was given between October 1986 and November 2007. In 98 patients a variety of first salvage regimens were employed, while 89 patients received platinum-based first salvage regimens. 9 patients received HD-chemotherapy. Details of first salvage regimens gives Table 4. 17 (17%) patients underwent additive surgical approach after first salvage chemotherapy, whereas complete resection was in 8 (47%) cases and incomplete resection of necrotic/ fibrotic tissue or mature teratoma in 9 (53%).
Univariate analysis of prognostic factors of overall survival after first salvage chemotherapy identified these significant prognostic factors of overall survival after first salvage chemotherapy: "age", "metastatic extent of disease at induction chemotherapy", "response to induction chemotherapy", "time from start of induction chemotherapy to progression", "hCG at relapse", "LDH at relapse", "number of metastatic sites at relapse", "first salvage chemotherapy" and "response to first salvage chemotherapy".
"Age" was an important prognostic factor of survival, p = 0,0227, patients older than 40 years had enhanced survival compared to younger patients at the time of diagnosis.
"Prior response to induction chemotherapy" was an impor tant predictor of survival after first salvage chemotherapy, p = <0,0001. 38 (39 %) patients with CR to Seventy four (76 %) of patients, with "progression from start of induction chemotherapy" less than 24 months had significantly adverse prognosis, with a median survival time 18,4 months (1,2 -229,4 months) compared to 24 (24 %) patients with "progression from start of induction chemotherapy" more than 24 months, with a median survival time 183,7 months (1,1 -183,7), p = 0,0471. 18/24 (75%) patients relapsed after more then 3 years from start of induction chemotherapy, with median time to progression 71,0 months (range 38,6-260,7 months) and have reached the best survival whitin the whole group of our patients with a median survival time 183,7 months ( 2-year survival of 72 %).
Level of "hCG at relapse" significantly influenced prognosis, p = 0,0302, but level of "AFP" was not significant predictor of survival, although a trend towards inferior survival was shown in patients with elevated AFP at relapse, p = 0,2080.
"LDH at relapse" was a significant prognostic factor of survival, p = 0,0223. 51 (58 %) patients with normal level of LDH at relapse had enhanced prognosis, with a median time of survival 38,7 months, compared to 38 (42 %) patients with elevated level of LDH, with a median time of survival 19,1 months.
"Number of metastatic sites at relapse" influenced survival, patients with 2 or more sites of metastases had adverse survival, p = 0,0095. "Cisplatin-based first salvage chemotherapy" significantly influenced prognosis, patients without cisplatin in first salvage regimen had an inferior survival, p = 0,0148.
Twenty seven patients with "first salvage regimen VIP" had enhanced prognosis, with median survival time of 37,1 months (2-year survival rate of 70%) compared to 38 patients with TIP, with median survival time of 31,5 months (2-year survival rate of 42%). Concurrently, patients with first salvage regimen VIP had enhanced prognosis compared to all patients with any other first salvage regimen, p = 0,0063.
"Response to first salvage chemotherapy" was an important predictor of survival, p = <0,0001. 24 (25 %) patients with CR to first salvage chemotherapy had enhanced survival, with a median survival time of 183,7 months, compared to 38 (40 %) patients with PRnm-, with a median survival time of 13,3 months, 8 (8 %) patients with PRnm+, with a median survival time of 8,8 months and 18 (19 %) patients with PGR, with a median survival time of 4,3 months.
Eight (8%) patients, who underwent complete additive surgical approach of residual disease after first salvage chemotherapy had enhanced survival, with median survival time of 79,9 months (2-year survival of 75%), compared to 9 (10%) patients with incomplete additive surgery, with a median survival time of 16,4 months (2-year survival of 33%) and 80 (82%) unoperated patients, with a median survival time of 25,4 months (2-year survival of 45%) . Table 5 gives results of the univariate analysis of survival after first salvage chemotherapy.
Univariate analysis of prognostic factors of event-free survival after first salvage chemotherapy:Univariate analysis identified these significant prognostic factors of event-free survival after first salvage chemotherapy: "time from start of induction chemotherapy to progression", "response to induction treatment", "number of metastatic sites at relapse", "first salvage chemotherapy" and "response to first salvage chemotherapy". Table 5 gives results of the univariate analysis of eventfree survival after first salvage chemotherapy.
Discussion
Progression after induction chemotherapy was observed in 98 patients with germ cell tumors. 76 (796%) patients relapsed within 24 months and 24 (24 %) patients after 24 months after induction chemotherapy (11/24 (46 %) patients after 60 months) which indicates the necessity to continue regular follow up in patients with germ cell tumors for the rest of their lives.
Our analysis concentrates mostly on prognostic features evaluable before first salvage chemotherapy. The overall estimated long-term survival was 24 %, which is comparable to other reports [0, 0, 0, 0, 0].
Fossa et al, determined in the multivariate analysis 3 independent prognostic factors of survival in patients with germ cell tumors progressing after platinum-based induction chemotherapy: "progression free interval", "response to induction chemotherapy" and "level of serum human chorionic gonadotropin (hCG) and alpha fetoprotein (AFP) at relapse", which were identical to our findings, except the "level of AFP at relapse", which was not a significant prognostic factor of survival for patients in our study [0] .
Gerl et al and Josefsen et al, defined "complete response to induction chemotherapy" as an independent positive prognostic factor of survival in patients with refractory or relapsed germ cell malignancy after conventional-dose cisplatin-based salvage chemotherapy, which was confirmed by our study [0, 0] .
Motzer et al identified significantly enhanced survival and/or response to salvage chemotherapy in patients with prior CR to induction chemotherapy, treatment with cis-platin based salvage regimen, a testis primary site, a normal human chorionic gonadotropin level, a normal serum lactate dehydrogenase level, one site of metastasis, and particularly poor survival in patients with prior incomplete response to induction chemotherapy. All prognostic factors of survival for relapsing patients identified in this study correspond also to our findings. Despite testis primary site was not a significant prognostic factor of survival in our group of patients, a trend towards inferior survival was shown in patients with extragonadal primary site [0] .
Nichols et al, determined as the most powerful prognostic parameter of survival for relapsing patients after CR to induction chemotherapy "long time to progression after induction chemotherapy" which was confirmed by our study as well [0] .
Study of Baniel et al, emphasized the fundamental role of surgery in patients with late relapse. Salvage chemotherapy was limitedly effective in patients progressing after 2 years from start of induction chemotherapy in their study [0] . In contrast, our results in patients with late relapse (24 patients, with a median time to progression 49,2 months) point out the role of salvage chemotherapy in these pa tients, because 16/24 pa tients had favourable response to first sal vage regimen (10 pa tients CR, 6 patients PRnm-) and additive surgical approach underwent just 2 out of these patients. 18/24 (75%) patients relapsed after more then 3 years from start of in duction che motherapy, and in ter estingly they have reached the best sur vival whitin the whole group of our patients ( 2-year survival of 72 %). All of them achieved favourable response to induction chemo therapy (10 patients CR, 8 patients PRnm-) and 14 (78%) of them favourable response to first salvage chemotherapy (9 pa tients CR, 5 patients PRnm-) con secu tively. Despite late re lapses generally considered as chemorefractory, cases of these pa tients with median time to progression 71,0 months (range 38,6-260,7 months) refer to noticeable sen si tivity to sal vage che mo therapy in these pa tients. We tried to evaluate the importance of additive surgical approach after salvage chemotherapy in our study as well. De spite finding out an enhanced overall survival in pa tients with com plete resection of residual disease after first sal vage che mo therapy, 8 patients with a median time of sur vival 79,9 months compared to 9 patients with in com plete sur gery, with a median time of survival 16,4 months and 80 unoperated pa tients, with a median time of sur vival 25,4 months, dem onstrated event-free survival was simi lar in these three groups of pa tients, with a median time of event-free survival 8,1 months, 7,2 months and 8,2 months re spec tively. The mani fest discrepancy be tween overall and event-free sur vival is hard to interpret. It is not evi dent, if an enhanced overall sur vival in 8 patients with com plete additive sur gical approach is caused by biological char ac ter is tics of their ma lig nant dis ease or due to given sur gery, since 6 of them relapsed after first salvage treatment again, while 1 patient only in retroperitoneum after prior com plete RPLA, 2 pa tients in lungs after prior complete pul mo nary metastasectomy, 1 pa tient in lungs and me di astinum after prior complete pul mo nary metastasectomy and 2 pa tients in other locations (retroperitoneum and CNS) after prior com plete pul mo nary metastasectomy after first salvage che mo therapy.
Horwich et al, referred to interesting fact in their study. El evated tumor markers at the time of progression in pa tients with late relapse were not an adverse factor of survival, this was the case when the progression period was short. 11/24 (46 %) pa tients with late relapse in our study had el evated AFP, 3/24 (13%) patients hCG and 1 (4 %) patient had el evated both tu mor markers at re lapse, while these pa tients achieved 2-year survival in 58 %, with median time of sur vival 38,8 months, which supported these findings as well [0] .
In summary, about 20-30 % of patients with advanced germ cell tumors are not cured by standard induction che mo therapy and require effective salvage treatment. Dem on strated longterm survival of our patients warrants the need to continue investigation of more effective salvage therapy. Prognostic features in patients with recurrent germ cell tumors evaluable before salvage therapy may direct the subsequent salvage treatment. Our study showed the in dis pensable evaluation of chemosenzitivity in patients with late relapses and thera peu tic value of additive surgical approach after salvage che motherapy in patients with reccurent germ cell tumors.
